6533b85efe1ef96bd12bfc5c

RESEARCH PRODUCT

Type 1 diabetic mellitus patients with increased atherosclerosis risk display decreased CDKN2A/2B/2BAS gene expression in leukocytes

Herminia González-navarroJuan F. AscasoVerónica Sánchez-garcíaAndrea Herrero-cerveraÁNgela VinuéSergio Martínez HervasDeborah J. BurksJosé T. Real

subject

Blood Glucose0301 basic medicineendocrine system diseasesCellular differentiationlcsh:Medicine0302 clinical medicineRisk FactorsRAR-related orphan receptor gammaimmune system diseasesLeukocytesIL-2 receptorDiabetisFOXP3Cell DifferentiationGeneral MedicineType 1 diabetes030220 oncology & carcinogenesisCytokinesRNA Long Noncodingmedicine.symptomAdultmedicine.medical_specialtyCD14T cellsInflammationPeripheral blood mononuclear cellGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesInternal medicinemedicineHumansRNA MessengerCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p15Glycated HemoglobinInflammationType 1 diabetesbusiness.industryResearchlcsh:RAtherosclerosismedicine.diseaseCardiovascular riskDiabetes Mellitus Type 1030104 developmental biologyEndocrinologyGene Expression RegulationCase-Control Studiesbusiness

description

Background Type 1 diabetes mellitus (T1DM) patients display increased risk of cardiovascular disease (CVD) and are characterized by a diminished regulatory T (Treg) cell content or function. Previous studies have shown an association between decreased CDKN2A/2B/2BAS gene expression and enhanced CVD. In the present study the potential relationship between CDKN2A/2B/2BAS gene expression, immune cell dysfunction and increased cardiovascular risk in T1DM patients was explored. Methods A cross-sectional study was performed in 90 subjects divided into controls and T1DM patients. Circulating leukocyte subpopulations analysis by flow cytometry, expression studies on peripheral blood mononuclear cell by qPCR and western blot and correlation studies were performed in both groups of subjects. Results Analysis indicated that, consistent with the described T cell dysfunction, T1DM subjects showed decreased circulating CD4+CD25+CD127− Treg cells. In addition, T1DM subjects had lower mRNA levels of the transcription factors FOXP3 and RORC and lower levels of IL2 and IL6 which are involved in Treg and Th17 cell differentiation, respectively. T1DM patients also exhibited decreased mRNA levels of CDKN2A (variant 1 p16Ink4a), CDKN2A (p14Arf, variant 4), CDKN2B (p15Ink4b) and CDKN2BAS compared with controls. Notably, T1DM patients had augmented pro-atherogenic CD14++CD16+-monocytes, which predict cardiovascular acute events and enhanced common carotid intima-media thickness (CC-IMT). Conclusions Decreased expression of CDKN2A/2B/2BAS in leukocytes associates with increased CC-IMT atherosclerosis surrogate marker and proatherogenic CD14++CD16+ monocytes in T1DM patients. These results suggest a potential role of CDKN2A/2B/2BAS genes in CVD risk in T1DM. Electronic supplementary material The online version of this article (10.1186/s12967-019-1977-1) contains supplementary material, which is available to authorized users.

yearjournalcountryeditionlanguage
2019-07-01Journal of Translational Medicine
10.1186/s12967-019-1977-1http://link.springer.com/article/10.1186/s12967-019-1977-1